Press Releases

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

September 21, 2023

Company announces 1-for-20 reverse stock split NEW HAVEN, CT – (September 21, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that [...]

Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

September 13, 2023

Company continues to make strides towards profitability NEW HAVEN, CT, Globenewswire – (September 13, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces its [...]

Precipio Announces Q2-2023 Shareholder Update Call

August 10, 2023

Conference Call to be held on August 17, 2023 at 5:00 PM EST NEW HAVEN, CT, (August 10th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

August 8, 2023

Advanced panel already generating six-figure pre-orders NEW HAVEN, CT, Globenewswire – (August 8, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch [...]

Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven

August 3, 2023

Revenue growth and customer pipeline advance the Company towards breakeven NEW HAVEN, CT, Globenewswire – (August 3, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

August 1, 2023

Revenue growth and customer pipeline advance the Company towards breakeven NEW HAVEN, CT, Globenewswire – (August 1, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

June 13, 2023

New panel will enable rapid, precise genetic profiling of patients with deadly disease NEW HAVEN, CT, (June 13th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

June 8, 2023

NEW HAVEN, CT, (June 8th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it has entered into securities purchase agreements with certain institutional investors [...]

Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects

June 7, 2023

Independent of revenue growth, these Projects expected to decrease cash burn by 25% in Q3 NEW HAVEN, CT, (June 7th, 2023) – Specialty cancer diagnostics company Precipio, [...]

Precipio Shares Growth Catalysts For HemeScreen

May 17, 2023

Q1 Results and catalysts show promising growth trajectory NEW HAVEN, CT, (May 17th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be discussing on today’s [...]

Precipio Announces Q1-2023 Shareholder Update Call

May 15, 2023

Conference Call to be held on May 17, 2023 at 5:00 PM EST NEW HAVEN, CT, (May 15th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

May 4, 2023

Customer’s pathology services annual revenues expected to exceed $1.5M NEW HAVEN, CT, Globenewswire – (May 4th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another [...]

Precipio Signs Another HemeScreen™ Customer

May 4, 2023

Customer’s revenues expected at $750K at full capacity NEW HAVEN, CT, Globenewswire – (May 4th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement [...]

Precipio Granted 180-day Extension From NASDAQ To Regain Compliance

April 27, 2023

Extension will enable the Company to execute on its growth and advance toward breakeven NEW HAVEN, CT, Globenewswire – (April 27th, 2023) – Specialty cancer diagnostics [...]

Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined

April 19, 2023

Q1-2023 product revenues approximately $0.76M exceeded the $0.66M combined revenue of Q3+Q4 2022 NEW HAVEN, CT, Globenewswire – (April 19th, 2023) – Specialty cancer diagnostics company [...]

Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call

March 28, 2023

Conference Call to be held on Monday, April 3rd, 2023 at 5:00 PM EST NEW HAVEN, CT, Globenewswire – (March 28th, 2023) – Specialty cancer diagnostics [...]

Precipio Ships First IV-Cell® Order to Major US Healthcare System

March 21, 2023

Products Division revenues begin to diversify beyond HemeScreen® NEW HAVEN, CT, Globenewswire – (March 21st, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first [...]

Precipio continues to sign up and onboard HemeScreen™ customers

March 7, 2023

Conversion from sales funnels developed with distribution partners alongside direct sales points to continued accelerated growth NEW HAVEN, CT, Globenewswire – (March 7th, 2023) – Specialty [...]

Precipio’s HemeScreen® Selected as 2022 Best New Product

February 14, 2023

HemeScreen® Technology and Product Line were recognized by Fisher Healthcare during recent National Sales Meeting “We are privileged to have Fisher Healthcare as a distribution [...]

Precipio Signs Another Major HemeScreen™ Customer

January 11, 2023

Customer’s initial annual revenue expected at $650K, $2.0M revenue at full capacity NEW HAVEN, CT, Globenewswire – (January 11th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Signs Additional Major HemeScreen™ Customer

December 6, 2022

Customer to begin gradually onboarding panels in Q1-2023, potential $1.2M revenue at full capacity NEW HAVEN, CT, Globenewswire – (December 6th, 2022) – Specialty cancer diagnostics [...]

Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference

November 7, 2022

Poster presents findings of a study of ~1000 patient samples demonstrating superior accuracy for HemeScreen™ MPN Assay NEW HAVEN, CT, Globenewswire – (November 7th, 2022) – [...]

Precipio Announces Third Quarter Shareholder Update Call

November 2, 2022

Conference Call to be held on Monday, November 14th, 2022 at 5:00 PM ET NEW HAVEN, CT, Globenewswire – (November 2nd, 2022) – Specialty cancer diagnostics [...]

Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™

September 15, 2022

Adding customer segment exceeding $100M in market potential NEW HAVEN, CT, Globenewswire – (September 15th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed a [...]

Sharon Robins Joins Precipio’s Products Division As Senior Director Of Laboratory & Hospital Sales

August 24, 2022

Precipio continues to build strong team in anticipation of substantial growth in the next 12 months NEW HAVEN, CT, Globenewswire – (August 24th, 2022) – Specialty [...]

Precipio Launches New 1-Step Technology For All HemeScreen Assays

August 16, 2022

New technology enables same day test results by eliminating extra confirmation step NEW HAVEN, CT, Globenewswire – (August 16th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Toni-Ann Mills Joins Precipio’s Products Division To Lead Channel Partner Training, Learning & Development

August 10, 2022

Precipio prepares to launch a nationwide HemeScreen sales effort of 250+ sales reps from AmerisourceBergen, ThermoFisher, and other distributors NEW HAVEN, CT, Globenewswire – (August [...]

Precipio Announces Second Quarter Shareholder Update Call

August 8, 2022

Conference Call to be held on Monday, August 15th, 2022 at 5:00 PM EST NEW HAVEN, CT, Globenewswire – (August 8th, 2022) – Specialty cancer diagnostics [...]

Precipio To Distribute HemeScreen® Through Fisher Healthcare Channel

July 20, 2022

Agreement Enhances Precipio’s Product Reach to US Laboratories NEW HAVEN, CT – (Globe Newswire) – (July 20th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today [...]

Precipio Requests That All Stockholders That Have Not Yet Voted, Proceed To Cast Their Vote

June 14, 2022

Meeting Adjourned, new meeting set for July 5th at 10am EDT NEW HAVEN, CT – (June 14th, 2022) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today [...]

Keith Meadors Joins Precipio To Lead Its Products Division

June 13, 2022

Seasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizations NEW HAVEN, CT – (Globenewswire) – (June 13th, 2022) – Specialty cancer [...]

Precipio Receives CE-IVD Certification To Market Multiple HemeScreen® Panels In Europe

May 24, 2022

This Regulatory Approval Opens the Company’s Reach to the European Market NEW HAVEN, CT – (Globenewswire) – (May 24th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Signs First IV-Cell Customer Agreement

May 10, 2022

Laboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potential NEW HAVEN, CT – (Globenewswire) – (May 10th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Precipio Customer American Oncology Network (AON) Selected To Present HemeScreen® Technology Case Study At Industry Leading Clinical Laboratory Conference

April 26, 2022

NEW HAVEN, CT – (Apr 26th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen, its [...]

Precipio Announces 2021 Fourth Quarter And Year-End Shareholder Update Call

March 22, 2022

Conference Call to be held on Monday, April 4th, 2022 at 5:00 PM EST NEW HAVEN, CT, Globenewswire – (Mar 22nd, 2022) – Specialty cancer diagnostics [...]

Precipio Inc. Announces The Resignation Of Its Chief Financial Officer And Appointment Of Interim CFO

March 21, 2022

NEW HAVEN, CT, (Mar 21st, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that Mr. Carl Iberger, Precipio’s CFO for the past five years, [...]

Precipio Releases Year-End 2021 Preliminary Unaudited Results And Outlook For 2022

February 24, 2022

NEW HAVEN, CT, (Feb 24th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced its unaudited and preliminary results for 2021. The Company anticipates posting [...]

New York State Approves Precipio’s HemeScreen For POL Clinical Use

November 18, 2021

New York Cancer & Blood POL will commence the use of HemeScreen in its laboratory NEW HAVEN, CT, (Nov 18th, 2021) – Specialty cancer diagnostics company Precipio, [...]

Precipio Announces Q3-2021 And Year-End Shareholder Update Call

November 1, 2021

Conference Call to be held on Monday, November 15th, 2021 at 5:00 PM EST NEW HAVEN, CT, (Nov 1st, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

American Oncology Network Partners With Precipio To Bring HemeScreen® Into AON’s Laboratory

August 26, 2021

HemeScreen Assays will enable AON to deliver rapid patient diagnostics for hematologic malignancies through advanced molecular screening technology New Haven, CT, and Fort Myers, FL [...]

Precipio Reschedules Q2-2021 Shareholder Update Call

August 20, 2021

Due to a schedule conflict, the call is moved to Thursday August 26th at 5:00PM EST NEW HAVEN, CT, (Aug 20th, 2021) – Specialty cancer diagnostics [...]

Precipio Announces Q2-2021 And Year-End Shareholder Update Call

August 12, 2021

Conference Call to be held on Monday, August 23rd, 2021 at 5:00 PM EST NEW HAVEN, CT, (Aug 12th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Announces Preliminary Unaudited Q2-2021 Revenues Of $2.3M

July 28, 2021

Increase of 65% YoY, and 29% from Q1-2021 due to strong Pathology Growth and HemeScreen NEW HAVEN, CT, (Jul 28th, 2021) – Specialty diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Terminates Its Equity Line

June 15, 2021

NEW HAVEN, CT, (Jun 15th, 2021) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that as part of management’s review of its current financing arrangements, it has [...]

Precipio Launches HemeScreen® Anemia Panel, A One-Of-Its-Kind Testing Tool

June 8, 2021

Laboratories can use this rapid, cost effective test to distinguish malignancy-driven anemia from other causes NEW HAVEN, CT, (June 8th, 2021) – Specialty diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Announces Q1-2021 And Year-End Shareholder Update Call

May 14, 2021

Conference Call to be held on Thursday, May 20th, 2021 at 5:00 PM EST NEW HAVEN, CT, (May 14th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Launches New HemeScreen Panel For AML, With An Unparalleled 4-Hour Turnaround-Time

May 10, 2021

Physician Office Laboratory (POL) Customers will be able to immediately integrate this important test into their current operations NEW HAVEN, CT, (May 10th, 2021) – Specialty [...]

Precipio Launches Its Rapid COVID-19 Antibody Test On Amazon Platform

May 3, 2021

Nirmidas’ test is available to POC healthcare providers with an Amazon business account NEW HAVEN, CT, (May 3rd, 2021) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...]

Current Signed Customers Expected To Generate $1M Annualized Reported Revenues From Precipio’s HemeScreen POL Offering By Q4-2021

April 26, 2021

Precipio reaffirms forecast that product revenues will reach approximately 50% of pathology revenue by the fourth quarter of 2021 NEW HAVEN, CT, (April 26th, 2021) – [...]

Precipio Enters Into An At-The -Market (ATM) Financing Arrangement

April 5, 2021

NEW HAVEN, CT, (April 5th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces a new “At-The-Market” (ATM) financing arrangement that improves its financing flexibility. As [...]

Precipio Announces 95% Annual Growth YoY And 180% Quarterly Growth YoY

March 30, 2021

HemeScreen projected to rapidly become a material revenue contributor in 2021 NEW HAVEN, CT, (March 30th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced its [...]

Precipio Announces Q4-2020 And Year-End Shareholder Update Call

March 18, 2021

Conference Call to be held on Wednesday, March 31st, 2021 at 5:00 PM EST NEW HAVEN, CT, (March 18th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Mr. Ron Andrews Joins Precipio’s Board Of Directors

March 3, 2021

Company Strengthens Depth of Expertise in Products Industry NEW HAVEN, CT, (March 3rd, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that Mr. Ron Andrews has joined the [...]

Mr. Richard Sandberg Is Appointed Chairman Of Precipio’s Board Of Directors

March 3, 2021

NEW HAVEN, CT, (March 3rd, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. [...]

Precipio Launches COVID-19 Antibody Testing At Point-Of-Care

January 28, 2021

Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POC NEW HAVEN, CT, (January 28th, 2021) – Specialty cancer diagnostics company Precipio, [...]

Precipio Signs HemeScreen™ Deals With Two Leading Oncology Groups

January 20, 2021

Partnership with ION Solutions expected to accelerate sales NEW HAVEN, CT, (January 20th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed agreements with two [...]

Precipio Signs Sales & Marketing Agreement For HemeScreen™ With Major Oncology Distributor

December 10, 2020

Thousands of Oncology Practices will gain access to HemeScreen POL program NEW HAVEN, CT, (December 10th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has entered [...]

Precipio Announces Q3-2020 Shareholder Update Call

November 11, 2020

Conference Call to be held on Thursday, November 19th, 2020 at 5:00 PM EST NEW HAVEN, CT, (November 11th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio & ADS Biotec Launch Seven Beta Sites For IV-Cell™

October 6, 2020

Prominent Laboratories in US and Europe will begin testing the media NEW HAVEN, CT, (October 6th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), along with [...]

Precipio Launches Its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel

September 22, 2020

Panel of clinically critical genes can yield same-day results outperforming major competitors NEW HAVEN, CT, (September 22nd, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...]

Precipio Announces A Shareholder Call To Discuss Its COVID-19 Progress And Future Plans

September 4, 2020

Ilan Danieli, Precipio CEO, will address questions from shareholders related to company COVID-19 strategy NEW HAVEN, CT, (September 4th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio & ADS Biotec Sign Global Distribution Agreement For IV-Cell™

August 20, 2020

Partnership is expected to accelerate product introduction to most major labs worldwide NEW HAVEN, CT, (August 20th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...]

Precipio Announces Q2-2020 Corporate Update Call For Shareholders

August 7, 2020

Conference Call to be held on Monday, August 17th, 2020 at 5:00 PM EST NEW HAVEN, CT, (August 7th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Launches Covid-19 Antibody Test In Its CLIA Laboratory

August 4, 2020

Test initially offered to Precipio’s customer base, then expanding distribution reach NEW HAVEN, CT, (August 4th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has [...]

Precipio Announces Commercial Launch Of Covid-19 Antibody Test

July 30, 2020

Test received FDA EUA; commercialization begins NEW HAVEN, CT, (July 30th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), is announcing its COVID-19 strategy, and its intent [...]

Precipio Announces Q2-2020 Unaudited Pathology Services Revenue Increased Approximately 50% Over Q1’20

July 22, 2020

NEW HAVEN, CT, (July 22nd, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced its preliminary unaudited revenues for its pathology services increased from $0.8M in Q1’20, [...]

Precipio Regains Listing Compliance With NASDAQ Minimum Bid Requirement

July 1, 2020

NEW HAVEN, CT, (July 1st, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has regained compliance with the Nasdaq listing requirements. On June 29, [...]

Precipio Adds Another HemeScreen™ Customer

June 9, 2020

Newly Created Reagent Rental Program Continues to Gain HemeScreen Adopters NEW HAVEN, CT, (June 9th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Cancer and Hematology [...]

Q1-2020 Reported Revenues Increase 77% Over Q4-2019 To $1.2M

May 15, 2020

Precipio Pathology Sales Performance Metrics Demonstrate Growth in Customer Acquisition, Retention, and Total Case Volume NEW HAVEN, CT, (May 15th, 2020) – Specialty cancer diagnostics company Precipio, [...]

Precipio Announces Q1-2020 Corporate Update Call For Shareholders

May 12, 2020

Conference Call to be held on Tuesday, May 19th, 2020 at 5:00 PM EST NEW HAVEN, CT, (May 12th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Launches New HemeScreen™ Reagent Rental Program

April 6, 2020

Oncology Practices Improve Patient care and Increase Revenue & Profit NEW HAVEN, CT, (April 6th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it [...]

Company Update During The COVID-19 Era

March 20, 2020

Letter to the Shareholders from the CEO NEW HAVEN, CT, (March 20th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), released today the following letter to shareholders [...]

Precipio Completes The Transaction With Poplar Healthcare’s Oncometrix Hematopathology Division

March 16, 2020

Customer base and sales team transition to Precipio, Doubling Revenues NEW HAVEN, CT, (March 16th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it [...]

Precipio Achieves Impressive Initial Results Of Artificial Intelligence Decision-Support Tool

February 26, 2020

Groundbreaking clinical and economic impact to be generated NEW HAVEN, CT, (February 26th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that preliminary results from [...]

Precipio In Advanced Discussions With Poplar Healthcare Towards A Multi-Faceted Strategic Partnership

February 18, 2020

NEW HAVEN, CT, (February 18th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it is in advanced discussions with Poplar Healthcare to establish a strategic partnership [...]

Precipio Provides Clarification To Amendment No.1 To Form S-1 Filing

January 28, 2020

NEW HAVEN, CT, (January 28th, 2020) – The management team of specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), would like to provide an explanation on the recent Amendment [...]

Precipio Provides Clarification To Recent S-1 Filing

January 15, 2020

NEW HAVEN, CT, (January 15th, 2020) – The management team of specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), would like to provide several clarification points related to the [...]

Precipio Announces Shareholder Update Call To Kick Off 2020

January 13, 2020

NEW HAVEN, CT, (January 13th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on Monday, January 20th at 5pm it will conduct a shareholder update [...]

Precipio Announces First IV-Cell™ Commercial Order From Northwell Health

December 17, 2019

Largest healthcare provider in New York becomes the first IV-Cell customer NEW HAVEN, CT, (December 17th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced [...]

Precipio Announces The Resignation Of Samuel Riccitelli And The Introduction Of Richard Sandberg To Its Board Of Directors

December 4, 2019

Douglas Fisher, MD will assume the role of interim Chairman of the Board NEW HAVEN, CT, (December 4th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...]

Precipio Wins $750,000 Pharma Project

November 14, 2019

Testing and revenues will begin in Q4 and continue into Q1-2020 NEW HAVEN, CT, (November 14th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced a substantial [...]

Precipio Reports Superior Performance For IV-Cell™ In Side-By-Side Analysis Conducted By Two Major External Laboratories

November 14, 2019

Testing yielded substantially better operational and clinical results, including the identification of a Leukemia missed when using a competing media NEW HAVEN, CT, (November 14th, 2019) – Specialty [...]

Precipio Announces Q3-2019 Corporate Update Call For Shareholders

November 4, 2019

Conference Call to be held on Wednesday, November 13th, 2019 at 5:30 PM EST NEW HAVEN, CT, (November 4th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Partners HealthCare And Precipio Enter Into Pathology Services Agreement

October 9, 2019

Continued Expansion of Academic Expertise Platform NEW HAVEN, CT, (October 9th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today a further expansion of its cancer [...]

Precipio Announces Shareholder Update Call On Commercial Progress

October 2, 2019

Conference call to be held Thursday October 10th at 5:00PM EST NEW HAVEN, CT, (October 2nd, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), will hold a [...]

Clinical Validations For IV-Cell™ And HemeScreen™ Completed

September 26, 2019

Orders expected from several major labs both domestically and internationally NEW HAVEN, CT, (September 26th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that as it [...]

Precipio And University Of Pennsylvania Enter Into Joint Collaboration Agreement For Pathology Diagnostics

September 5, 2019

First cases already diagnosed and reported by Penn expert pathologists NEW HAVEN, CT, (September 5th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today a major [...]

Precipio Pathology Sales Metrics Demonstrate Continuous Improvement In Q2 2019

August 13, 2019

Three key metrics indicate growth over prior Quarter and same Quarter of 2018 NEW HAVEN, CT, (August 13th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Precipio Announces Q2-2019 Corporate Update Call For Shareholders

August 13, 2019

Conference Call to be held on Wednesday, August 21st, 2019 at 5:00 PM EST NEW HAVEN, CT, (August 13, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Global Expansion Efforts Begin Yielding Results

July 22, 2019

Asia is the first Key Geographic Focal Point NEW HAVEN, CT, (July 22nd, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that in conjunction with [...]

Precipio And H3 Biomedicine Sign Second Development Agreement

June 25, 2019

Companies to create a panel amplifying targeted regions of key cancer genes NEW HAVEN, CT, (June 25th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced the [...]

Precipio CEO Provides Update Letter To Shareholders

June 17, 2019

NEW HAVEN, CT, (June 17th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides an update to its shareholders. Dear Investors: We are all aware of the [...]

Precipio Signs Exclusive Manufacturing Agreement For IV-Cell™

June 4, 2019

NEW HAVEN, CT, (June 4th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has entered into an exclusive subcontracting manufacturing agreement with diagnostics manufacturing [...]

Precipio Pathology Sales Performance Metrics Demonstrate Substantial Improvement In Q1-2019

May 30, 2019

Three key metrics are leading indicators of continuous revenue growth NEW HAVEN, CT, (May 30th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), today provides shareholders with [...]

Precipio CEO Enrolls In Long Term Stock Purchase Plan

May 23, 2019

NEW HAVEN, CT, (May 23, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that, as previously stated, Ilan Danieli, Precipio’s CEO, has enrolled in a [...]

Precipio Regains Nasdaq Listing Compliance

May 15, 2019

NEW HAVEN, CT, (May 15, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on May 15, 2019 the Company received a letter from Nasdaq informing [...]

Precipio Conducts IV-Cell™ Validation Trial With A Prominent Laboratory

May 6, 2019

NEW HAVEN, CT, (May 06, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it is in the process of completing a trial of its Proprietary [...]

Precipio Successfully Completes Nasdaq Hearing Process

May 3, 2019

Company is expected to regain listing compliance upon completion of the remaining 10-day requirement NEW HAVEN, CT, (May 03, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Precipio Reminder Of Corporate Update Shareholder Call

May 1, 2019

Conference Call to be held Monday May 6th, 2019 at 5:00pm Eastern Time NEW HAVEN, CT, (May 01, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), will [...]

Precipio Signs First Major International Services Contract

April 29, 2019

Contract expected to generate over $1.5M in revenues annually NEW HAVEN, CT, (April 29, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has [...]

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

April 26, 2019

Company announces 1-for-15 reverse stock split NEW HAVEN, CT, (April 26, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has implemented a 1-for-15 [...]

Precipio Launches Global Expansion Strategy

April 24, 2019

Precipio to capitalize on powerful data and expertise to grow business globally NEW HAVEN, CT, (April 24, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch [...]

Mr. Ori Karev Joins Precipio Executive Team As Chief Strategy Officer

April 18, 2019

Precipio to expand its reach globally NEW HAVEN, CT, (April 18, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced today that Mr. Ori Karev has joined the [...]

Precipio Announces 2018 Year-End Corporate Update Call For Shareholders

April 15, 2019

Conference Call to Be Held On Monday, May 6th, 2019 at 5:00 PM ET NEW HAVEN, CT, (April 15th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Identifies Manufacturer For Its IV-Cell Media

April 9, 2019

Manufacturing Partner enables Precipio to address customer demand and plans for global distribution NEW HAVEN, CT, (April 9th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced today [...]

Precipio’s HemeScreen™ Adopted By Methodist Health

April 3, 2019

New Molecular Screening Assay Technology Gains Traction NEW HAVEN, CT, (April 3, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that Methodist Hospital, located in Memphis, [...]

Precipio CEO Issues Shareholder Update Letter

March 11, 2019

NEW HAVEN, CT, (March 11th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), issues the following letter from CEO Ilan Danieli. Dear Shareholders, Following our recent [...]

Precipio Provides Corporate Update Shareholder Call

February 18, 2019

Conference Call to be held Thursday February 21st, 2019 at 4:30pm Eastern Time NEW HAVEN, CT, (February 18th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO),will [...]

Precipio 2018 Revenues Increase 66% Over 2017; Company Takes Substantial Cost-Cutting Measures Towards Profitability

February 14, 2019

Shareholder call scheduled for February 21st at 4:30PM EST NEW HAVEN, CT, (February 14th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO),announced today its preliminary unaudited [...]

Makati Medical Center In The Philippines Adopts Precipio’s ICE COLD-PCR Mutation Enrichment Technology For Liquid Biopsies

January 15, 2019

One of Nation’s Premier Hospitals to Become Central Laboratory for Liquid Biopsies NEW HAVEN, CT, (January 15th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that Makati [...]

Precipio Announces First US Government Customer For ICE COLD-PCR™ Mutation Enrichment Technology

January 10, 2019

Department of Defense Approves Precipio as a Vendor for its Liquid Biopsy Testing NEW HAVEN, CT, (January 10th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Precipio Files Patent For HemeScreen™, Its Novel Molecular Assay

January 8, 2019

Commercialization of assay underway with both in-house testing and hospital sales NEW HAVEN, CT, (January 8th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the [...]

Precipio Reports Strong Mid-Quarter Growth

December 12, 2018

Key Metrics Indicate Continued Growth QoQ for Fourth Quarter 2018 NEW HAVEN, CT, (December 12th, 2018) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that based [...]

Precipio Announces $1.2 Million Securities Purchase Agreement With Participation From Members Of Its Board Of Directors, And Other Investors

December 4, 2018

NEW HAVEN, CT, (December 4th, 2018) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has entered into a $1.2 million Securities Purchase Agreement with [...]

Precipio Announces Third Quarter 2018 Corporate Update Call For Shareholders

November 19, 2018

Conference Call to Be Held Monday, November 19, 2018 at 5:00 PM ET NEW HAVEN, CT, (November 15th, 2018) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be [...]

Proxy And Special Shareholder Meeting Letter From CEO

November 16, 2018

CEO to share a few thoughts in advance of the upcoming shareholder call on Monday, November 19th at 5PM EST NEW HAVEN, CT, (November 16th, [...]

Webinar To Highlight Technology Underlying Precipio’s ICE COLD-PCR On November 20, 2018

November 14, 2018

Current Status, Existing and Future Applications of COLD-PCR for Cancer and Prenatal Diagnosis to Be Presented NEW HAVEN, CT, (November 14th, 2018) – Specialty diagnostics company Precipio, [...]

Precipio And PerkinElmer Collaborate To Provide Solutions For Liquid Biopsy Testing Workflows

November 1, 2018

Precipio ICE COLD-PCR™ reagents will be sold with PerkinElmer DNA/RNA extraction and isolation products NEW HAVEN, CT, (November 1st, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Expands ICE COLD-PCR™ Menu For Breast, Colon And Endometrial Cancers

October 23, 2018

Ultra-sensitive assays for PIK3CA exons 9 & 20 detect mutations that impact critical therapeutic decisions NEW HAVEN, CT, (October 23rd, 2018) – Precipio, Inc. (NASDAQ: PRPO), announced today [...]

Innovation Behind Precipio’s ICE-COLD PCR™ Platform Spotlighted In Media

October 18, 2018

Articles Highlight Scientific and Economic Advantages Provided by Precipio’s Technology NEW HAVEN, CT, (October 18th, 2018) – The scientific and economic advantages of the proprietary, ultra-sensitive [...]

Precipio Launches HemeScreen™, A Disruptive, Proprietary Molecular Test For Hematologic Cancers

October 3, 2018

Impacts a $100M annual US laboratory market by reducing testing costs through a simple, screening assay NEW HAVEN, CT, (October 3rd, 2018) – Specialty cancer diagnostics [...]

Precipio Granted 180 Day NASDAQ Extension To Regain Compliance

September 27, 2018

Enables Company to execute on strategic and commercial initiatives with the goal of meeting the minimum $1.00 price target NEW HAVEN, CT, (September 27th, 2018) – [...]

Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering

September 20, 2018

New reagent examines most relevant EGFR exons that impact therapeutic decisions for lung cancer patients NEW HAVEN, CT, (September 20th, 2018) – Specialty cancer diagnostics company Precipio, [...]

Precipio Announces Third Quarter 2018 Revenues Estimated At 2.4 Times Year-Over-Year Q3-2017

September 16, 2018

Fourth consecutive Quarter of Triple-Digit YoY Quarterly Growth; Triple YTD Revenues Over Same Period Last Year NEW HAVEN, CT, (October 16th, 2018) – Specialty cancer diagnostics [...]

Precipio Reminds Investors Of Conference Call With Management For Corporate Update And Second Quarter Results

August 22, 2018

Provides participation details for Thursday, August 23 call NEW HAVEN, CT, (August 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), wishes to remind investors and [...]

Precipio Announces Second Quarter 2018 Financial Results And Provides Corporate Update

August 17, 2018

Conference call with management to be held Thursday August 23, 2018 at 09:00 Eastern Time NEW HAVEN, CT, (August 17th, 2018) – Specialty cancer diagnostics company Precipio, [...]

Precipio Appoints New Board Member To Replace Departing Director

August 9, 2018

Kathy LaPorte brings 30-year track record of VC success financing and operating innovative biopharma, diagnostics and healthcare companies NEW HAVEN, CT, (August 09th, 2018) – Specialty [...]

Precipio Announces 213% Year-Over-Year Revenue Growth In Preliminary Q2-2018 Results

July 18, 2018

Third consecutive quarter of triple-digit YoY Quarterly growth NEW HAVEN, CT, (July 18th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced preliminary second quarter [...]

Precipio And Nucleai Partner To Develop Artificial Intelligence-Powered Hemepath Solution

June 26, 2018

System will support Hematopathologists in accurately identifying abnormalities to ensure diagnostic accuracy NEW HAVEN, CT, (June 26th, 2018) – Precipio, Inc. (NASDAQ: PRPO), announced today an agreement with [...]

Precipio Updates Commercial Pipeline For Its ICE-COLD PCR™ Liquid Biopsy Technology

June 19, 2018

Trials underway at five laboratories and two diagnostic equipment companies NEW HAVEN, CT, (June 19th, 2018) – Precipio, Inc. (NASDAQ: PRPO), today detailed its pipeline of high-volume potential [...]

Precipio Inc. Announces Adjournment Of Annual Meeting Of Shareholders

June 15, 2018

NEW HAVEN, CT, (June 15th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that the Company’s 2018 Annual Meeting of Shareholders, originally scheduled for [...]

Precipio Reminds Shareholders To Vote Before The Annual General Meeting On June 15, 2018

June 14, 2018

NEW HAVEN, CT, (June 14th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today reminded its shareholders to vote on proposals 1-6 in accordance with the [...]

Precipio Reminds Shareholders To Vote Before The Annual General Meeting On June 15, 2018

June 12, 2018

NEW HAVEN, CT, (June 12th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today reminded its shareholders to vote on proposals 1-6 in accordance with the [...]

Precipio Strengthens Patent Portfolio With Expanded Reagent Claims For Its Liquid Biopsy Enabling DNA Mutation Enrichment Technology

June 6, 2018

NEW HAVEN, CT, (June 06th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the award of US patent No. 9,957,556 entitled FULL COLD-PCR ENRICHMENT [...]

Precipio Launches Liquid Biopsy DNA Enrichment Sales In Europe With First Order

May 24, 2018

$10 million annual Europe market anticipated with $1 million annual addressable sales potential from local Italy partner/i> NEW HAVEN, CT, (May 24th, 2018) – Specialty cancer [...]

Potential Sequential Revenue Run-Rate Growth Of 30% Over Q1, Based On Preliminary April Results

May 22, 2018

Revenue growth accelerating as new sales initiatives and expanded team gain traction NEW HAVEN, CT, (May 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today [...]

Precipio Launches ICE COLD-PCR™ Liquid Biopsy Reagent For Pancreatic Cancer

May 17, 2018

Ultra-sensitive enrichment reagent enables development of low cost detection tests, allowing optimized patient treatment NEW HAVEN, CT, (May 17th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Announces Preliminary Q1 2018 Year-Over-Year Revenue Increase Of 286%

May 14, 2018

Growth resulting from commercial team reorganization, product and service cross-selling, and increased business stabilization NEW HAVEN, CT, (May 14th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Announces Participation Details For Upcoming Shareholder Conference Call

April 26, 2018

NEW HAVEN, CT, (April 26th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides details of its previously announced upcoming shareholder conference call scheduled for Monday [...]

Precipio Completes A $3M Convertible Debt Facility

April 23, 2018

Management focuses on growth opportunities NEW HAVEN, CT, (April 23rd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it entered into a convertible [...]

Precipio In Strategic Partnership Discussions For Proprietary Cytogenetics Media IV-Cell

April 18, 2018

NEW HAVEN, CT, (April 18th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today it is in active licensing discussions with several potential partners regarding [...]

Precipio Releases Its 2017 10-K, Files A Form S-1, And Hosts Fourth Quarter And Full Year Update Call

April 17, 2018

Management to provide strategic business update to shareholders NEW HAVEN, CT, (April 17th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that on April [...]

Precipio Launches ICE COLD-PCR™ Research Access Program For Cancer Centers

April 11, 2018

Complimentary Precipio ICE COLD PCR™ reagents now available to advance body of research and accelerate market expansion NEW HAVEN, CT, (April 11th, 2018) – Specialty cancer [...]

Important JAMA Article Underscores Superiority Of Precipio’s Liquid Biopsy Core Technology

April 3, 2018

Study cites major accuracy flaws in predominant liquid biopsy platforms offered by competitors NEW HAVEN, CT, (April 03rd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Precipio Files Patent For Non-Invasive Cell Capture Device For Gynecological Cancer Detection

March 28, 2018

In collaboration with Yale, feminine panty liner designed to remove obstacles to early detection NEW HAVEN, CT, (March 28th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Precipio Enters India Liquid Biopsy Market With Adoption By Leading Laboratory

March 26, 2018

CORE Diagnostics to transition to Precipio’s price competitive ICE COLD-PCR™ platform NEW HAVEN, CT, (March 26th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced [...]

Precipio Restructures Capitalization Table

March 22, 2018

Investors to convert preferred shares and exercise warrants NEW HAVEN, CT, (March 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), in an 8-K issued today [...]

Precipio Integrates Cost Reducing And Fast Turnaround “High Resolution Melt” Into Liquid Biopsy Platform

March 20, 2018

Enhances competitive advantage as industry’s most cost effective solution NEW HAVEN, CT, (March 20th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today it has [...]

Precipio Settles Lawsuit With Crede Capital

March 13, 2018

Completes Restructuring of close to 95% Transgenomic Liabilities NEW HAVEN, CT, (March 13th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today it has settled [...]

Key Measure Of Precipio’s Pathology Sales Growth 4X Prior Quarter

February 22, 2018

Strong indications of academic-level pathology market adoption and sales uptake NEW HAVEN, CT, (February 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that [...]

Precipio Launches Unique Lung Cancer Monitoring Test For Therapy Resistance

February 15, 2018

New test fulfills promise of liquid biopsies to cost effectively monitor patients NEW HAVEN, CT, (February 15th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...]

Precipio Announces Q4 2017 Revenue At 350% Of Previous Quarter

February 9, 2018

First post-merger quarter to turn the corner and demonstrate growth NEW HAVEN, CT, (February 09th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces preliminary, unaudited [...]

Precipio Enters Japanese Liquid Biopsy Market With First Hospital Sale

February 6, 2018

First ICE-COLD PCR™ order generated from distribution partnership with Sowa Trading Company NEW HAVEN, CT, (February 06th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces [...]

Precipio Commences Validation Study Of Proprietary IV-Cell Cytogenetics Media At University Of Pennsylvania

January 22, 2018

NEW HAVEN, CT, (January 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it is collaborating with the cytogenetics laboratory at the University of [...]

Precipio Appoints New Sales VP To Manage Diagnostics Sales Expansion

January 16, 2018

Sales growth acceleration plan to triple size of oncologist/hospital sales team in 2018 NEW HAVEN, CT, (January 16th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Yale Study Demonstrates Four-Fold Superiority Of Academic Level Diagnostic Accuracy

January 10, 2018

Study further shows ~73% of cases which academic pathologists determined were previously misdiagnosed, have definite or possible material impact on patient treatment plans NEW HAVEN, [...]